Targeting specific receptors to treat tumors in patients with neurofibromatosis type 1.
TAM receptor inhibition in NF1-associated peripheral nerve sheath tumors
This study is looking at how a drug called cabozantinib might help stop tumor growth in people with neurofibromatosis type 1 (NF1) by blocking certain receptors, and it hopes to find new ways to improve treatment for those living with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-10914770 on NIH RePORTER |
What this research studies
This research investigates the use of a drug called cabozantinib to inhibit certain receptors involved in the growth of tumors associated with neurofibromatosis type 1 (NF1). The study focuses on understanding how these receptors contribute to the development of benign and malignant tumors in NF1 patients. By using advanced animal models that mimic human disease, researchers aim to determine if targeting these receptors can prevent the progression of tumors and improve patient outcomes. The findings from this research could lead to new treatment options for individuals affected by NF1.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with neurofibromatosis type 1, particularly those with plexiform neurofibromas or atypical neurofibromas.
Not a fit: Patients without a diagnosis of neurofibromatosis type 1 or those who do not have associated tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic approach to prevent tumor progression in patients with neurofibromatosis type 1.
How similar studies have performed: Previous research has shown promising results in targeting similar receptors for tumor treatment, indicating potential for success in this approach.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Clapp, David W — Indiana University Indianapolis
- Study coordinator: Clapp, David W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.